H. Groen

Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.

H. Groen, E. Vellenga, N. Mulder, 1994, Blood.

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.

I. C. Kok, H. Groen, G. Hospers, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.

H. Groen, N. Mulder, E. de Vries, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematopoietic effects of recombinant human interleukin-3 and interleukin-6

G. Veldhuis, P. Willemse, D. Sleijfer, 1997 .

Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1

H. Groen, L. de Leij, E. de Vries, 1997, Cancer Immunology, Immunotherapy.

Effects of recombinant human interleukin-6 with or without recombinant human granulocyte-macrophage colony-stimulating factor before and after chemotherapy

H. Groen, N. Mulder, E. Vries, 1997 .

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours

H. Groen, R. Paridaens, A. Oosterom, 2000, British Journal of Cancer.